Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2206-2214

  Biron, Bethany ^a   Beck, Katie ^a   Dyer, David ^a   Mattix, Marc ^d   Twenhafel, Nancy ^b   Nalca, Aysegul ^c  

^a Center for Aerobiological Sciencesa and Pathology Division   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c BROWN UNIVERSITY   (United States)

^d WIL RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; OBILTOXAXIMAB; SODIUM CHLORIDE; ANTIINFECTIVE AGENT; ANTITOXIN; ETI-204; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PRIORITY JOURNAL; RABBIT MODEL; SURVIVAL; ANIMAL; BACILLUS ANTHRACIS; BACTEREMIA; BACTERIAL SPORE; BRAIN; EXPOSURE; MICROBIOLOGY; PATHOLOGY; RABBIT; SURVIVAL ANALYSIS;

ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTITOXINS; BACILLUS ANTHRACIS; BACTEREMIA; BRAIN; DOXYCYCLINE; FEMALE; INHALATION EXPOSURE; MALE; RABBITS; SPORES, BACTERIAL; SURVIVAL ANALYSIS;

EID: 84928910510     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04593-14     Document Type: Article

References (57)

1. Dixon TC, Meselson M, Guillemin J, Hanna PC. 1999. Anthrax. N Engl J Med 341:815-826. http://dx.doi.org/10.1056/NEJM199909093411107.
2. Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD. 2004. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev 68:617-629. http://dx.doi.org/10.1128/MMBR.68.4.617-629.2004.
3. Baillie LW. 2006. Past, imminent and future human medical countermeasures for anthrax. J Appl Microbiol 101:594-606. http://dx.doi.org/10.1111/j.1365-2672.2006.03112.x.
4. Bouzianas DG. 2007. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism. Expert Rev Anti Infect Ther 5:665-684. http://dx.doi.org/10.1586/14787210.5.4.665.
5. Brachman PS. 1980. Inhalation anthrax. Ann N Y Acad Sci 353:83-93. http://dx.doi.org/10.1111/j.1749-6632.1980.tb18910.x.
6. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. 2006. Systematic review: A century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 144:270-280. http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00009.
7. Kobiler D, Weiss S, Levy H, Fisher M, Mechaly A, Pass A, Altboum Z. 2006. Protective antigen as a correlative marker for anthrax in animal models. Infect Immun 74:5871-5876. http://dx.doi.org/10.1128/IAI.00792-06.
8. Sela-Abramovich S, Chitlaru T, Gat O, Grosfeld H, Cohen O, Shafferman A. 2009. Novel and unique diagnostic biomarkers for Bacillus anthracis infection. Appl Environ Microbiol 75:6157-6167. http://dx.doi.org/10.1128/AEM.00766-09.
9. Friedlander AM. 2000. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis 20:335-349.
10. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K. 1999. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281:1735-1745.
11. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K, Working Group on Civilian Biodefence. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236 - 2252. http://dx.doi.org/10.1001/jama.287.17.2236.
12. Spiers EM. 2010. A history of chemical and biological weapons. Reaktion Books, London, England.
13. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M, Greene C, Griffith KS, Guarner J, Hadler JL, Hayslett JA, Meyer R, Petersen LR, Phillips M, Pinner R, Popovic T, Quinn CP, Reefhuis J, Reissman D, Rosenstein N, Schuchat A, Shieh WJ, Siegal L, Swerdlow DL, Tenover FC, Traeger M, Ward JW, Weisfuse I, Wiersma S, Yeskey K, Zaki S, Ashford DA, Perkins BA, Ostroff S, Hughes J, Fleming D, Koplan JP, Gerberding JL, National Anthrax Epidemiologic Investigation Team. 2002. Investigation of bioterrorism- related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8:1019-1028. http://dx.doi.org/10.3201/eid0810.020353.
14. Passalacqua KD, Bergman NH. 2006. Bacillus anthracis: interactions with the host and establishment of inhalational anthrax. Future Microbiol 1:397-415. http://dx.doi.org/10.2217/17460913.1.4.397.
15. Rossi CA, Ulrich M, Norris S, Reed DS, Pitt LM, Leffel EK. 2008. Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax. Infect Immun 76:5790-5801. http://dx.doi.org/10.1128/IAI.00520-08.
16. Tournier JN, Quesnel-Hellmann A, Cleret A, Vidal DR. 2007. Contribution of toxins to the pathogenesis of inhalational anthrax. Cell Microbiol 9:555-565. http://dx.doi.org/10.1111/j.1462-5822.2006.00866.x.
17. Collier RJ, Young JA. 2003. Anthrax toxin. Annu Rev Cell Dev Biol 19:45-70. http://dx.doi.org/10.1146/annurev.cellbio.19.111301.140655.
18. Mourez M. 2005. Anthrax toxins. Rev Physiol Biochem Pharmacol 152: 135-164. http://dx.doi.org/10.1007/s10254-004-0028-2.
19. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361:135-144. http://dx.doi.org/10.1056/NEJMoa0810603.
20. Peterson JW, Comer JE, Baze WB, Noffsinger DM, Wenglikowski A, Walberg KG, Hardcastle J, Pawlik J, Bush K, Taormina J, Moen S, Thomas J, Chatuev BM, Sower L, Chopra AK, Stanberry LR, Sawada R, Scholz WW, Sircar J. 2007. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun 75:3414-3424. http://dx.doi.org/10.1128/IAI.00352-07.
21. Chen Z, Moayeri M, Purcell R. 2011. Monoclonal antibody therapies against anthrax. Toxins 3:1004-1019. http://dx.doi.org/10.3390/toxins3081004.
22. Ionin B, Hopkins RJ, Pleune B, Sivko GS, Reid FM, Clement KH, Rudge TL Jr, Stark GV, Innes A, Sari S, Guina T, Howard C, Smith J, Swoboda ML, Vert-Wong E, Johnson V, Nabors GS, Skiadopoulos MH. 2013. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Clin Vaccine Immunol 20:1016- 1026. http://dx.doi.org/10.1128/CVI.00099-13.
23. Leffel EK, Bourdage JS, Williamson ED, Duchars M, Fuerst TR, Fusco PC. 2012. Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. Clin Vaccine Immunol 19:1158-1164. http://dx.doi.org/10.1128/CVI.00240-12.
24. Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA, Workgroup on Anthrax Clinical Guidelines. 2014. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis http://dx.doi.org/10.3201/eid2002.130687.
25. Albrink WS. 1961. Pathogenesis of inhalation anthrax. Bacteriol Rev 25: 268-273.
26. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr. 1997. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278: 399-411. http://dx.doi.org/10.1001/jama.1997.03550050061035.
27. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL, Zaki S, Popovic T, Meyer RF, Quinn CP, Harper SA, Fridkin SK, Sejvar JJ, Shepard CW, McConnell M, Guarner J, Shieh WJ, Malecki JM, Gerberding JL, Hughes JM, Perkins BA, Anthrax Bioterrorism Investigation Team. 2001. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg Infect Dis 7:933-944. http://dx.doi.org/10.3201/eid0706.010604.
28. Malkevich NV, Hopkins RJ, Bernton E, Meister GT, Vela EM, Atiee G, Johnson V, Nabors GS, Aimes RT, Ionin B, Skiadopoulos MH. 2014. Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans. Antimicrob Agents Chemother 58:3618- 3625. http://dx.doi.org/10.1128/AAC.02295-13.
29. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L. 2005. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 73:795- 802. http://dx.doi.org/10.1128/IAI.73.2.795-802.2005.
30. Vasconcelos D, Barnewall R, Babin M, Hunt R, Estep J, Nielsen C, Carnes R, Carney J. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest 83:1201-1209. http://dx.doi.org/10.1097/01.LAB.0000080599.43791.01.
31. Kummerfeldt CE. 2014. Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist 7:101-109. http://dx.doi.org/10.2147/IDR.S47305.
32. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, Iverson BL, Georgiou G. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20: 597-601. http://dx.doi.org/10.1038/nbt0602-597.
33. Little SF, Leppla SH, Cora E. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 56:1807-1813.
34. Little SF, Novak JM, Lowe JR, Leppla SH, Singh Y, Klimpel KR, Lidgerding BC, Friedlander AM. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142:707-715. http://dx.doi.org/10.1099/13500872-142-3-707.
35. Leysath CE, Monzingo AF, Maynard JA, Barnett J, Georgiou G, Iverson BL, Robertus JD. 2009. Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen. J Mol Biol 387:680-693. http://dx.doi.org/10.1016/j.jmb.2009.02.003.
36. Sloat BR, Cui Z. 2006. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res 23:262-269. http://dx.doi.org/10.1007/s11095-005-9078-7.
37. Twenhafel NA. 2010. Pathology of inhalational anthrax animal models. Vet Pathol 47:819-830. http://dx.doi.org/10.1177/0300985810378112.
38. Leffel EK, Pitt MLM. 2012. Characterization of new and advancement of existing animal models of Bacillus anthracis infection, p 81-98. In Swearengen JR (ed), Biodefense research methodology and animal models, 2nd ed. CRC Press, Boca Raton, FL.
39. Yee SB, Hatkin JM, Dyer DN, Orr SA, Pitt ML. 2010. Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment. Comp Med 60:461-468.
40. Goossens PL. 2009. Animal models of human anthrax: The quest for the holy grail. Mol Aspects Med 30:467-480. http://dx.doi.org/10.1016/j.mam.2009.07.005.
41. Grinberg LM, Abramova FA, Yampolskaya OV, Walker DH, Smith JH. 2001. Quantitative pathology of inhalational anthrax. I: quantitative microscopic findings. Mod Pathol 14:482-495.
42. Little SF, Ivins BE. 1999. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect 1:131-139. http://dx.doi.org/10.1016/S1286-4579(99)80004-5.
43. Connell SR, Tracz DM, Nierhaus KH, Taylor DE. 2003. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 47:3675-3681. http://dx.doi.org/10.1128/AAC.47.12.3675-3681.2003.
44. Smith K, Leyden JJ. 2005. Safety of doxycycline and minocycline: A systematic review. Clin Ther 27:1329-1342. http://dx.doi.org/10.1016/j.clinthera.2005.09.005.
45. Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58:256-265. http://dx.doi.org/10.1093/jac/dkl224.
46. Saivin S, Houin G. 1988. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15:355-366. http://dx.doi.org/10.2165/00003088-198815060-00001.
47. Federal Register. 2001. Prescription drug products; doxycycline and penicillin G. Procaine administration for inhalational anthrax (postexposure). Fed Regist 66:55679-55682.
48. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. 2008. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis http://dx.doi.org/10.3201/eid1404.070969.
49. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
50. Hartings JM, Roy CJ. 2004. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. J Pharmacol Toxicol Methods 49:39-55. http://dx.doi.org/10.1016/j.vascn.2003.07.001.
51. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122:982-992.
52. Weiss S, Kobiler D, Levy H, Pass A, Ophir Y, Rothschild N, Tal A, Schlomovitz J, Altboum Z. 2011. Antibiotics cure anthrax in animal models. Antimicrob Agents Chemother 55:1533-1542. http://dx.doi.org/10.1128/AAC.01689-10.
53. Russell PK. 2007. Project BioShield: what it is, why it is needed, and its accomplishments so far. Clin Infect Dis 45(Suppl 1):S68 -S72. http://dx.doi.org/10.1086/518151.
54. Hao L, Zheng F, Xiong S, Hu D, Lv H, Tang Q, Yang J, Feng Z, Wang C, Zhu J. 2014. Preparation and evaluation of human-murine chimeric antibody against protective antigen of Bacillus anthracis. Int J Mol Sci 15:18496-18507. http://dx.doi.org/10.3390/ijms151018496.
55. Migone TS, Bolmer S, Zhong J, Corey A, Vasconcelos D, Buccellato M, Meister G. 2014. Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax. Antimicrob Agents Chemother 59:1145-1151. http://dx.doi.org/10.1128/AAC.04606-14.
56. Fritz DL, Jaax NK, Lawrence WB, Davis KJ, Pitt ML, Ezzell JW, Friedlander AM. 1995. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest 73:691-702.
57. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P, et al. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 167: 1239-1243. http://dx.doi.org/10.1093/infdis/167.5.1239.